Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug development should rely on fewer, larger trials, ex-Lilly exec Thompson tells FDA.

Executive Summary

DRUG DEVELOPMENT SHOULD RELY ON FEWER, LARGER STUDIES, ex-LILLY EXEC Leigh Thompson, MD/PhD, suggested at a Feb. 5 Center for Drug Evaluation & Research seminar. "We can get very few, large, well-designed, complex studies that have far more power in terms of the analyses we do and not have all of these small wasteful studies exposing people to placebo and doses that aren't any good," Thompson said. He advised FDA to "teach industry how to do a small number of studies" and to "coach people to think beyond mean and standard deviation."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel